Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer

Posted on by

Dr. Barnes brings more than 25 years of biotech leadership expertise and a proven track record in advancing transformative early-stage therapies Interim CEO Tal Zaks, M.D., Ph.D., to continue as executive chair BOSTON, Jan. 27, 2025 /PRNewswire/ — Averna Therapeutics, Inc. (“Averna”;…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.